

Page 3, following line 8, insert as a centered heading

--The Invention--;

Page 4, line 9, delete "to have" in its second occurrence;

Page 11, following line 20, insert as a separate paragraph --The terms and

expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalent of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.--.

In the Claims:

Without prejudice, cancel claims 1 to 15 and add claims 16 to 31.

Sub B2  
--16. A transdermal therapeutic system with a content of a first active ingredient selected from <sup>1/2</sup> candesartan or one of its pharmaceutically suitable esters or salts.

17. The transdermal therapeutic system of claim 16 wherein candesartan is the active ingredient.

A2  
18. The transdermal therapeutic system of claim 16 wherein candesartan cilexetil is the active ingredient.

19. The transdermal therapeutic system of claim 16 wherein an ammonium and/or alkali metal salt of candesartan is the active ingredient.

20. The transdermal therapeutic system of claim 16 further comprising at least a second active ingredient.

BEST AVAILABLE COPY

21. The transdermal therapeutic system of claim 20 wherein the second active ingredient enhances the effect of candesartan.

22. The transdermal therapeutic system of claim 20 wherein the second active ingredient is a diuretic and/or a Ca channel blocker.

23. The transdermal therapeutic system of claim 16 in the form of a plaster with an impermeable covering layer and a detachable protective layer, in particular in the form of a matrix system (or) of a membrane system.

24. The transdermal therapeutic system of claim 23 wherein the covering layer comprises a polyester, polypropylene, polyurethane or polyethylene, and is optionally metalized or pigmented.

25. The transdermal therapeutic system of claim 23 wherein the detachable protective layer comprises a polyester, polypropylene, polysiloxane, polyacrylate, ethylene/vinyl acetate, polyurethane, polyisobutene or paper with a silicone and/or a polyethylene coating.

26. The transdermal therapeutic system of claim 23 wherein the system is a matrix system comprising:

- a an impermeable covering layer; *backing layer*
- b at least one active ingredient-containing contact adhesive matrix layer or at least one ingredient-containing matrix layer coated with a contact adhesive;
- c a detachable protective layer; and *adhesive layer*

BEST AVAILABLE COPY

an active ingredient selected from candesartan or one of its pharmaceutically acceptable esters or salts.

Sub C 27. The transdermal therapeutic system of claim 26 wherein the matrix layer comprises a polyacrylate, silicone, polyisobutylene, rubber, rubber-like synthetic homo-, co- or block polymers, butyl rubber, styrene/isoprene copolymer, polyurethanes, copolymers of ethylene, polysiloxanes or styrene/butadiene copolymer.

Sub B4 28. The transdermal therapeutic system of claim 23 wherein the membrane system comprises:

- a an impermeable covering layer;
- b an active ingredient-containing reservoir or an active ingredient-containing reservoir layer;
- c a microporous or semipermeable membrane;  
an optional contact adhesive layer; and  
an active ingredient selected from candesartan or one of its pharmaceutically acceptable esters or salts.

29. The transdermal therapeutic system of claim 28 wherein the membrane comprises an inert polymer, in particular polypropylene, polyvinyl acetate, polyamide, ethylene/vinyl acetate copolymer or silicone.

30. The transdermal therapeutic system of the claim 16 further comprising a permeation promoter.

BEST AVAILABLE COPY

31. The transdermal therapeutic system of claim 30 wherein the permeation promoter is selected from the group consisting of monohydric and/or polyhydric aliphatic, cycloaliphatic and/or aromatic-aliphatic alcohols each with up to 8 C atoms, and/or polyethylene glycol; alcohol/water mixtures; saturated and/or unsaturated fatty alcohols each with 8-18 C atoms; terpenes; mixtures of terpenes and ethanol and/or propylene glycol; tea tree oil; saturated and/or unsaturated cyclic ketones; alkyl methyl sulfoxides; saturated and/or unsaturated fatty acids each with 8-18 C atoms; the esters and salts thereof; natural vitamin E; synthetic vitamin E and/or vitamin E derivatives; sorbitan fatty acid esters and ethoxylated sorbitan fatty acid esters; Azone (laurocapram); Azone mixed with alcohols; urea; 1-alkylpyrrolidone; block copolymers of polyethylene glycol and dimethylsiloxane with cationic groups at one end; folate-polyethylene glycol liposome, proliposome; polyoxyethylene 10 stearyl ether; mixture of polyoxyethylene 10 stearyl ether and glyceryl dilaurate; dodecyl 2-(N,N-dimethylamino)propanoate and/or dodecyl 2-(N,N-dimethylamino)propionate N-acetylproline esters with more than 8 C atoms; nonionic surfactants, esters of polyoxyethylene; ethosome (phospholipid vesicle); dimethyl(arylimino)sulfurane; mixture of oleic acid analogs and propylene glycol; mixture of padimate O, octyl salicylate, octyl methoxycinnamate and laurocapram and/or mixtures thereof.

REMARKS

BEST AVAILABLE COPY

The specification and claims of the above-identified application have been amended to a form more consistent with U.S. practice. No new matter has been added.